Anti CD47 Drugs Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Anti CD47 Drugs Market is segmented By Target Disease Indication (Acute Myeloid Leukemias, Non-Hodgkin Lymphoma, Colorectal Cancers, Diffuse Large Bcell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral Muscositis, Small Cell Lung Cancers), By Type of Molecule (Biologics, Small Molecules), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa). The report offers the value (in USD Billion) for the above-mentioned segments.

Competitive overview of Anti CD47 Drugs Market

The major players operating in the anti CD47 drugs market include Bristol Myers Squibb, ALX Oncology, Trillium Therapeutics, Innovent Biologics, Forty Seven, Abpro, Apmonia Therapeutics, Arch Oncology, Aurigene, EpicentRx, ImmuneOncia Therapeutics, ImmuneOnco Biopharmaceuticals, KAHR Medical, Light Chain Bioscience, and Morphiex.

Anti CD47 Drugs Market Leaders

  • Bristol Myers Squibb
  • ALX Oncology
  • Trillium Therapeutics
  • Innovent Biologics
  • Forty Seven
*Disclaimer: Major players are listed in no particular order.

Anti CD47 Drugs Market - Competitive Rivalry, 2023

Market Concentration Graph

Anti CD47 Drugs Market

Market Consolidated
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
*Source: Coherent Market Insights

Anti CD47 Drugs Market Report Snapshots

Buy Now